Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
14.45
-0.09 (-0.62%)
Apr 13, 2026, 12:54 PM EDT - Market open
Cullinan Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
109
Market Cap
874.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 18.94M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.72B |
| Xencor | 125.58M |
| Theravance Biopharma | 107.46M |
| Evommune | 13.00M |
| Janux Therapeutics | 10.00M |
| Aktis Oncology | 6.50M |
| Compass Therapeutics | 850.00K |
CGEM News
- 4 weeks ago - Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Cullinan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 3 months ago - Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones - GlobeNewsWire
- 4 months ago - Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting - GlobeNewsWire
- 4 months ago - Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 5 months ago - Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations - PRNewsWire